Urine Free Dopamine in Normal Primigravid Pregnancy and Women Taking Oral Contraceptives

1981 ◽  
Vol 61 (4) ◽  
pp. 423-428 ◽  
Author(s):  
C. M. Perkins ◽  
K. W. Hancock ◽  
G. F. Cope ◽  
M. R. Lee
Keyword(s):  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Oral Contraceptives ◽  
Normal Volunteer ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Normal Menstrual Cycle

1. Urine free dopamine was estimated at predetermined points of the menstrual cycle in normal volunteer subjects and in women taking a combined oral contraceptive. 2. There was no alteration in 24 h urine dopamine during the normal menstrual cycle but, in contrast, combined oral contraceptives produced a fall which recovered premenstrually. 3. In 19 primigravid subjects 24 h urine free dopamine was estimated at monthly intervals throughout pregnancy and at the time of the postnatal examination. 4. Urine dopamine was elevated throughout pregnancy when compared with postnatal values. Women receiving an oral progestogen contraceptive at the time of the postnatal examination showed a further fall in urine dopamine.

▾Mercilon - a new low-dose combined oral contraceptive

1989 ◽  
Vol 27 (13) ◽  
pp. 51-52
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Low Dose ◽  
Combined Oral Contraceptives ◽  
Younger Women ◽  
Combined Oral Contraceptive

Mercilon (Organon) is a new combined oral contraceptive “developed with the mature pill user in mind”. Each tablet contains ethinyloestradiol 20µg + desogestrel 150µg. It is a lower dose version of Marvelon (ethinyloestradiol 30µg + desogestrel 150µg),1 which is intended for younger women, and like Marvelon contains the highly selective progestagen desogestrel, which is said to be more progestagenic and less androgenic than other commonly used progestagens.2 Like other monophasic combined oral contraceptives, Mercilon is taken daily for 21 days, followed by a 7-day break.

scholarly journals Extrapolation Of A Controversial Subject In Pregnancy And Puerperium: The Influence Of Combined Oral Contraceptive Use Over Body Mass Index And Biliary Symptoms

2012 ◽  
Vol 18 (2) ◽  
pp. 72-76
Author(s):  
Irina Tica ◽  
V.I. Tica ◽  
Claudia Mihailov ◽  
A. Mitroi
Keyword(s):  
Body Mass Index ◽  
Oral Contraceptive ◽  
Body Mass ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
The Body ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Oral Contraceptive Use ◽  
Ultrasound Evaluation

AbstractIntroduction and aim: Because for the majority of women one of the most unwanted effect of combined oral contraceptive use is considered to be weight increasement, our study aim was to find out if there is a correlation between the use of combined oral contraceptives in the present or past and the body mass index in a group of pregnant, puerperal and matching control patients.Material, patients and method:In a prospective cohort (Regional University Hospital - Constanţa), 176 patients were included in 3 groups: pregnant, puerperal and matching non-pregnant women (control). For each patient a chart was considered, with the following parameters, age, height, weight, BMI, type of diet, use of combined oral contraceptives in the present or in the past (more than 6 months), ultrasound evaluation of gallbladder’ content.Conclusion:In our study, the use of combined oral contraceptives was not correlated with a high BMI but it seems to correlate with a higher incidence of biliary dyspeptic symptoms in patients without biliary sludge or stones.

scholarly journals Use of Combined Oral Contraceptives and Headaches

Medicina ◽  
2011 ◽  
Vol 47 (5) ◽  
pp. 36
Author(s):  
Diana Šimonienė ◽  
Virginija Vanagienė ◽  
Birutė Žilaitienė ◽  
Tadas Vanagas
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Sexual Partner ◽  
Odds Ratio ◽  
Contraceptive Use ◽  
Daily Activities ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Oral Contraceptive Use ◽  
Steady Sexual Partner

Objective. The study was designed to examine the certain patterns of combined oral contraceptive use in women of childbearing potential and evaluate the relationship between the use of combined oral contraceptives and headaches, bad habits, type of work, and concomitant diseases. Material and Methods. In total, 194 randomly selected women aged 18 to 40 years who visited a gynecologist for preventive gynecological examination were surveyed. Respondents were categorized as combined oral contraceptive users (n=116; study group) and nonusers (n=78; control group). An anonymous questionnaire developed by the authors of this study and a standardized scale called the Migraine Disability Assessment Scale (MIDAS) were used for the survey. Results. A multivariate logistic regression analysis demonstrated a significantly higher prevalence of combined oral contraceptive use in women older than 20 years (odds ratio, 6.0; 95% CI, 2.6–14), better educated women (odds ratio, 5.7; 95% CI, 2.1–15.2), and women reporting a steady sexual partner (odds ratio, 4.0; 95% CI, 1.5–11.0). Relationship between headaches and use of combined oral contraceptives as well as other factors were analyzed in a group of 178 respondents; the rest 16 respondents reported not having headaches at all. The prevalence of reported minimal-tomild and moderate-to-severe impact of headaches on daily activities did not differ significantly between the study and control groups, women with and without bad habits, and white-collar and bluecollar groups (P>0.05). However, women with concomitant diseases significantly more often reported moderate-to-severe impact on daily activities due to headaches (P<0.01). Differences in impact of headaches on daily activities between women using combined oral contraceptives containing 20 or less μg of ethinylestradiol and 30 or more μg of ethinylestradiol did not differ significantly. Conclusions. The prevalence of combined oral contraceptive use was higher in women older than 20 years, better educated women, and women reporting a steady sexual partner. The impact of headaches on daily activities did not differ significantly between the combined oral contraceptive users and nonusers.

Benefits and risks of oral contraception

2010 ◽  
pp. 2191-2195
Author(s):  
John Guillebaud
Keyword(s):  
Colorectal Cancer ◽  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Oral Contraceptives ◽  
Oral Contraception ◽  
Combined Oral Contraceptives

Efficacy of the ‘pill’ as an oral contraceptive—users of combined oral contraceptives (COC) must understand the importance of not lengthening the pill-free (contraception-deficient) time, and be appropriately advised if prescribed enzyme-inducing drugs. Noncontraceptive benefits of COC use—these include fewer disorders of the menstrual cycle and less risk of colorectal cancer and cancers of the ovary and endometrium, which may sometimes provide the principal indication for prescription....

Topical issues in combined oral contraceptives usage

GYNECOLOGY ◽  
2018 ◽  
Vol 20 (2) ◽  
pp. 60-63
Author(s):  
S O Dubrovina
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Premenstrual Syndrome ◽  
Emergency Contraception ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Economic Justification

The article presents topical issues of combined oral contraceptive (COC) use: among women with obesity, the effectiveness of COC in the management of premenstrual syndrome, the risk of thrombosis among women using of COCs and the economic justification for screening thrombophilia before the appointment of combined oral contraceptives, and the "quick start" of COCs after emergency contraception.

Cardiometabolic and Hemostatic Profiles of Women Carriers of Hemoglobin Variants Using Combined Oral Contraceptives

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4851-4851
Author(s):  
Junia Raquel Dutra Ferreira ◽  
Caroline Conceição Guarda ◽  
Rayra Pereira Santiago ◽  
Luane Rocha ◽  
Jessica SANTOS Ferreira ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
Density Lipoprotein ◽  
Reproductive Age ◽  
Lipoprotein Cholesterol ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Hemoglobin Variants ◽  
D Dimer

Abstract Introduction: Several studies reported combined contraceptives influence in hemostatic and lipid profile besides the concern about the thromboembolism and cardiovascular risks due to the steroids hormones use. As women with hemoglobin (Hb) variants have a pre-existing inflammatory condition and considering the high frequency of hemoglobin variant worldwide, this study aims to evaluate the association of hematological, lipid, glicemic, inflammatory and hemostatic profiles in women using combined oral contraceptives and carriers of hemoglobin variants. Methods: We performed a cross-sectional study including 591 women in reproductive-age. We investigated their hemoglobin profile and COCs use. Of them, we included 60 women with HbAA, 21 with HbAC, 25 with HbAS and 7 with HbSC profiles, all of them combined oral contraceptives users. Among those combined oral contraceptives nonusers, 9 were HbAC and 19 HbSC. We evaluated fasting serum glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), C-reactive protein (CRP), fibrinogen, D-dimer and hematological profile among the studied groups. This study was conducted in accordance and approved by the Research Ethics Committee of the Fundação Oswaldo Cruz - FIOCRUZ, Brazil; and also with the Helsinki Declaration of 1975, and its revisions. Mann-Whitney U tests were used to compare two groups of values within the same variable. Results: We observed significant differences in some hematological and cardiometabolic parameters in women carriers of different Hb variants and using COCs. We found relevant increases in CRP levels in HbSC and HbAC women that seem to be associated with different types of progestins present in combined oral contraceptives formulations. Also, combined oral contraceptives use seems to be associated with decreased HDL-c levels in HbAC women. Otherwise, D-dimer levels were increased in all women with Hb variants, independently of the contraceptive use. Conclusions: Although combined oral contraceptive remains an important method to prevent unintended pregnancy, our data suggest that contraception in women carriers of Hb variants, including those in heterozygosis, should be carefully evaluated, especially, considering the pre-existent inflammatory and pro-thrombotic conditions that together with combined oral contraceptive use may result in additional health problems, such as cardiovascular and thromboembolic diseases. Disclosures No relevant conflicts of interest to declare.

Urinary melatonin, LH, oestradiol, progesterone excretion during the menstrual cycle or in women taking oral contraceptives

1987 ◽  
Vol 116 (1) ◽  
pp. 145-149 ◽  
Author(s):  
Jocelyne Brun ◽  
Bruno Claustrat ◽  
Michel David
Keyword(s):  
Oral Contraceptive ◽  
Menstrual Cycle ◽  
Urinary Excretion ◽  
Oral Contraceptives ◽  
Coefficient Of Variation ◽  
Luteal Phase ◽  
Positive Relationship ◽  
Follicular Phase ◽  
The Other ◽  
Normal Women

Abstract. Nocturnal urinary excretion of melatonin, LH, progesterone and oestradiol was measured by radioimmunoassay in nine normal women during a complete cycle. In addition, these hormonal excretions were studied in two women taking an oral contraceptive. A high within-subject coefficient of variation was observed for melatonin excretion in the two groups. In the nine normal cycling women, melatonin excretion was not decreased at the time of ovulation, but was significantly increased during the luteal phase compared with that of the follicular phase (P < 0.01). These data are consistent with a positive relationship between melatonin and progesterone during the luteal phase. In the two women under an oral contraceptive, melatonin excretion was found within the same range as for the other nine. The results are discussed in terms of pineal investigation in human.

Sign in / Sign up

Export Citation Format

Share Document